Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

Inclusion Criteria:

Only patients who meet all the following criteria can be included in the group:

1. CD7-positive refractory or relapsed T-cell malignancies with progression orintolerance after all standard treatments, limited prognosis from currentlyavailable treatments and no available treatment options (e.g. HSCT or chemotherapy).

2. Tumor cells in bone marrow or cerebrospinal fluid are positive for CD7 antigen byflow cytometry or tumour tissue is positive for CD7 by immunohistochemistry (CD7antigen positivity by flow cytometry: >80% of tumour cells expressing CD7 with amean fluorescence intensity [MFI] of CD7 similar to that of normal T cells areconsidered to have fully positive expression; >80% of tumor cells expressing CD7 butwith an MFI of CD7 at least 1 log lower than that of normal T cells are consideredto have low expression [dim]; tumor cells with a CD7 expression rate between 20-80%are considered to have partial expression; CD7 antigen positivity by pathologicalimmunohistochemistry: >30%);

3. Male or female, age 1-70 years;

4. No severe allergic constitution;

5. Eastern Cooperative Oncology Group (ECOG) performance status score (Oken et al.,

1982. of 0-2;

6. Life expectancy of at least 60 days as determined by the investigator;

7. Provide a signed informed consent form prior to any screening procedures; subjectsvolunteering to participate in the study should be capable of understanding andsigning the informed consent form and be willing to follow the study visit scheduleand associated study procedures as specified in the protocol. Subjects aged 19-70years old need to be sufficiently aware and capable of signing the informed consentform; subjects aged 1-7 years can be recruited after legal guardians or patientadvocates sign the informed consent form; subjects aged 8-18 years need to besufficiently aware and able to sign the informed consent form, and their legalguardians or patient advocates also need to sign the informed consent form.

Exclusion Criteria:

Patients with at least one of the following conditions are excluded:

1. Intracranial hypertension or unconscious;

2. Acute heart failure or severe arrhythmia;

3. Acute respiratory failure;

4. Other types of malignant tumors;

5. Diffuse intravascular coagulation;

6. Serum creatinine and/or blood urea nitrogen over 1.5 times the normal value;

7. Sepsis or other uncontrolled infection;

8. Uncontrolled diabetes mellitus;

9. Severe psychological disorder;

10. Obvious cranial lesions by cranial MRI;

11. Allergic constitution;

12. Organ recipients;

13. Pregnant or breastfeeding;

14. Active, uncontrolled infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or treponema pallidum (TP).